These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25136033)

  • 1. Response.
    Moon BS; Cho YH; Jeong WJ; Choi KY
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25136033
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
    Cristóbal I; Rincón R; Manso R; Rojo F; García-Foncillas J
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25136032
    [No Abstract]   [Full Text] [Related]  

  • 3. KRAS and cancer stem cells in APC-mutant colorectal cancer.
    Fearon ER; Wicha MS
    J Natl Cancer Inst; 2014 Feb; 106(2):djt444. PubMed ID: 24491303
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
    Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
    J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Stem cell theory of colorectal cancer and its connection with molecular-biological data].
    Hagymási K; Molnár B; Sipos F; Galamb O; Tulassay Z
    Orv Hetil; 2007 Apr; 148(17):779-85. PubMed ID: 17452307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arl4c is a key regulator of tubulogenesis and tumourigenesis as a target gene of Wnt-β-catenin and growth factor-Ras signalling.
    Matsumoto S; Fujii S; Kikuchi A
    J Biochem; 2017 Jan; 161(1):27-35. PubMed ID: 28053143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt/beta-catenin signaling in cancer stemness and malignant behavior.
    Fodde R; Brabletz T
    Curr Opin Cell Biol; 2007 Apr; 19(2):150-8. PubMed ID: 17306971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling.
    Horst D; Chen J; Morikawa T; Ogino S; Kirchner T; Shivdasani RA
    Cancer Res; 2012 Mar; 72(6):1547-56. PubMed ID: 22318865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt signalling pathway in the serrated neoplastic pathway of the colorectum: possible roles and epigenetic regulatory mechanisms.
    Fu X; Li L; Peng Y
    J Clin Pathol; 2012 Aug; 65(8):675-9. PubMed ID: 22412046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Wnt signaling in colon cancer stem cells.
    de Sousa EM; Vermeulen L; Richel D; Medema JP
    Clin Cancer Res; 2011 Feb; 17(4):647-53. PubMed ID: 21159886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA binding protein RBM3 increases β-catenin signaling to increase stem cell characteristics in colorectal cancer cells.
    Venugopal A; Subramaniam D; Balmaceda J; Roy B; Dixon DA; Umar S; Weir SJ; Anant S
    Mol Carcinog; 2016 Nov; 55(11):1503-1516. PubMed ID: 26331352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment.
    Kim JY; Lee HY; Park KK; Choi YK; Nam JS; Hong IS
    Oncotarget; 2016 Apr; 7(15):20395-409. PubMed ID: 26967248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer.
    Moor AE; Anderle P; Cantù C; Rodriguez P; Wiedemann N; Baruthio F; Deka J; André S; Valenta T; Moor MB; Győrffy B; Barras D; Delorenzi M; Basler K; Aguet M
    EBioMedicine; 2015 Dec; 2(12):1932-43. PubMed ID: 26844272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of Wnt5a, APC, β-catenin and their clinical significance in human colorectal adenocarcinoma].
    Cao YC; Yang F; Liu XH; Xin X; Wang CC; Geng M
    Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):674-8. PubMed ID: 23159080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology of colorectal cancer.
    Saif MW; Chu E
    Cancer J; 2010; 16(3):196-201. PubMed ID: 20526096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Setting future standards for KRAS testing in colorectal cancer.
    van Krieken H; Tol J
    Pharmacogenomics; 2009 Jan; 10(1):1-3. PubMed ID: 19102707
    [No Abstract]   [Full Text] [Related]  

  • 17. A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans.
    Scholtka B; Schneider M; Melcher R; Katzenberger T; Friedrich D; Berghof-Jäger K; Scheppach W; Steinberg P
    Cancer Epidemiol; 2009 Aug; 33(2):123-9. PubMed ID: 19679059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
    de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
    J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel multiple, monoallelic KRAS mutations at codon 12 and 13.
    Keller G; Geist B; Slotta-Huspenina J; Langer R; Nagl F; Fend F; Höfler H; Perren A
    Int J Cancer; 2009 Dec; 125(11):2744-5. PubMed ID: 19521964
    [No Abstract]   [Full Text] [Related]  

  • 20. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.
    Mologni L; Dekhil H; Ceccon M; Purgante S; Lan C; Cleris L; Magistroni V; Formelli F; Gambacorti-Passerini CB
    Cancer Res; 2010 Sep; 70(18):7253-63. PubMed ID: 20823162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.